CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib

Mantle cell lymphoma (MCL) is a rare subtype of non‐Hodgkin's lymphoma, which is characterized by overexpression of cyclin D1. Although novel drugs, such as ibrutinib, show promising clinical outcomes, relapsed MCL often acquires drug resistance. Therefore, alternative approaches for refractory...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Kagiyama, Yuki, Fujita, Shuhei, Shima, Yutaka, Yamagata, Kazutsune, Katsumoto, Takuo, Nakagawa, Makoto, Honma, Daisuke, Adachi, Nobuaki, Araki, Kazushi, Kato, Ayako, Inaki, Koichiro, Ono, Yoshimasa, Fukuhara, Suguru, Kobayashi, Yukio, Tobinai, Kensei, Kitabayashi, Issay
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177787/
https://ncbi.nlm.nih.gov/pubmed/33792119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14905
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados